NasdaqHealth CareManaged Health CareS&P MidCap 400
$103.63
+0.17 (+0.16%)
Close of Nov 06, 2026 · end-of-day data
HQY 8-K filings, explained
Every material Form 8-K HealthEquity has filed with the SEC since February 18, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
HealthEquity terminated Chief Commercial Officer Michael Fiore without cause, effective October 5, 2026, according to an 8-K filed October 9, 2026. The company said his duties will be redistributed among other members of management, and the filing does not name a replacement.
Termination without cause effective October 5, 2026
Responsibilities of the Chief Commercial Officer to be redistributed to other management team members
Severance and benefits follow the employment agreement, as detailed in the May 13, 2026 proxy statement, conditioned on a release of claims and continued compliance with restrictive covenants
Outstanding equity awards to be treated under the 2014 and 2024 Stock Incentive Plans and related award agreements
HealthEquity appointed Noémie Heuland, Chief Financial Officer of Moody's Corporation, to its Board of Directors effective September 24, 2026, expanding the Board to eleven members from ten. The filing also discloses that the company paid approximately $146,519 to Moody's controlled subsidiaries in the fiscal year ended January 31, 2026 for bond ratings services and data sets, and expects to pay more than $120,000 in the fiscal year ending January 31, 2027.
Heuland appointed effective September 24, 2026; Board expands to 11 members from 10, with nine of the 11 independent.
Heuland will serve on the Audit and Risk Committee and the Cybersecurity and Technology Committee.
Paid approximately $146,519 to Moody's controlled subsidiaries in the fiscal year ended January 31, 2026 for ratings services and data sets.
Expects payments to Moody's controlled subsidiaries to exceed $120,000 in the fiscal year ending January 31, 2027.
HealthEquity reported second-quarter results for the period ended July 31, 2026, with revenue up 8%, net income up 10% and GAAP diluted earnings per share of $0.78, compared with $0.68 a year earlier. The company also raised its fiscal 2027 guidance, now expecting revenue of $1.411 billion to $1.421 billion and GAAP net income of $2.88 to $2.96 per diluted share.
Q2 revenue rose 8% to $350.7 million; net income rose 10% to $65.6 million
Adjusted EBITDA rose 11% to $167.0 million, with margin at 48% versus 46% a year earlier
Fiscal 2027 outlook: revenue $1.411 billion to $1.421 billion; non-GAAP EPS $4.66 to $4.73
Repurchased $108.1 million of stock in the quarter; $948.4 million remained authorized as of July 31, 2026
HealthEquity reported results for the first quarter ended April 30, 2026, with revenue up 7% to $354.6 million and net income up 29% to $69.4 million. The company raised its fiscal 2027 outlook, and its board authorized an additional $1.0 billion of share repurchases in May 2026, which gives shareholders a higher outlook and more buyback capacity.
Revenue rose 7% to $354.6 million from $330.8 million a year earlier.
Net income was $69.4 million, or $0.82 per diluted share, compared with $53.9 million, or $0.61, in the prior-year quarter.
Adjusted EBITDA rose 17% to $164.5 million, and its margin widened to 46% from 42%.
For fiscal 2027 (ending January 31, 2027), management expects revenue of $1.410 billion to $1.420 billion and GAAP net income of $2.88 to $2.95 per diluted share.
HealthEquity disclosed that on May 5, 2026, six executives, including CEO Scott Cutler and CFO James Lucania, signed amendments to their employment agreements that enlarge severance payments and benefits. The changes add target cash bonus payments to severance, and for Cutler, a higher bonus multiple and longer salary continuation after a change in control. The filing also describes new equity vesting terms for awards granted after March 25, 2026.
On May 5, 2026, six executives signed amendments to their employment agreements providing enhanced severance.
Upon a termination without cause or resignation for good reason, Cutler's severance includes 12 months of base salary plus his target cash bonus; after a change in control it is 150% of target bonus plus 18 months of base salary.
Other executives receive 12 months of base salary plus target cash bonus if terminated on or within 18 months after a change in control.
Full amendment text and award agreements will be filed with the next Form 10-Q.
HealthEquity said it will terminate the employment of Chief Technology Officer Eli Rosner without cause, effective April 17, 2026. Sunil Rajasekar, the company's Executive Vice President, Chief Product and Strategy Officer, will oversee the technology organization from that date.
Eli Rosner, Chief Technology Officer, will leave the company without cause effective April 17, 2026.
Sunil Rajasekar, Executive Vice President, Chief Product and Strategy Officer, will take over oversight of the technology organization.
Rosner's severance is tied to a release of claims and continued compliance with restrictive covenants, per terms described in the May 13, 2025 proxy statement.
Rajasekar has served in his current role since January 2026; earlier he was CEO of Billtrust through August 2025.
HealthEquity appointed William Gassen, president and CEO of Sanford Health, to its board effective March 26, 2026, expanding the board from nine to ten members. The filing also discloses that Sanford Health is a customer, with $123,923 in revenue to HealthEquity in the fiscal year ended January 31, 2026, and expected revenue above $120,000 in the fiscal year ending January 31, 2027.
Gassen joins the board effective March 26, 2026, and will serve on the Audit and Risk Committee and the Talent, Compensation and Culture Committee.
The board expanded to ten members from nine; the company says eight of the ten directors are independent.
HealthEquity received $123,923 from Sanford Health in the fiscal year ended January 31, 2026, and expects more than $120,000 in the fiscal year ending January 31, 2027.
HealthEquity reported results for the fiscal year and fourth quarter ended January 31, 2026. Fiscal year revenue rose 9% to $1.31 billion and net income rose 123% to $215.2 million, or $2.46 per diluted share. The company raised its fiscal 2027 outlook, which now calls for revenue of $1.405 billion to $1.415 billion and GAAP net income of $2.78 to $2.85 per diluted share.
Fiscal 2026 revenue of $1.31 billion, up 9% from $1.20 billion; net income of $215.2 million, or $2.46 per diluted share, versus $96.7 million, or $1.09, a year earlier.
Fourth quarter revenue of $334.6 million, up 7%; net income of $49.7 million, or $0.58 per diluted share, versus $0.30 a year earlier.
Fiscal 2027 outlook (year ending January 31, 2027): revenue of $1.405 billion to $1.415 billion and Adjusted EBITDA of $618 million to $628 million.
Repurchased $301.7 million of common stock in fiscal 2026; $177.7 million remained authorized for repurchase as of January 31, 2026.
HealthEquity said its HSA Assets reached $36.5 billion as of January 31, 2026, up 14% from a year earlier, and its HSA count rose 7% to 10.6 million. The company reaffirmed its fiscal 2026 and 2027 outlook and said fiscal 2026 results are expected to be near the top end of previously provided ranges, which signals strong sales for shareholders while full fiscal 2027 guidance is deferred to March.
Fourth-quarter new HSAs from sales rose 17% year over year, and the company reported more than one million new HSA accounts from sales for fiscal 2026.
Total HSA Assets were $36.5 billion, up 14% from $32.1 billion, with HSA investments up 26% to $18.5 billion.
Total Accounts reached 17.8 million, up 4%, and the company expects to provide full fiscal 2027 guidance when it reports year-end results in March.
The fourth-quarter and fiscal 2026 results conference call is scheduled for March 17, 2026, at 4:30 p.m. Eastern Time.
HealthEquity reported results for its fiscal third quarter ended October 31, 2025, with revenue up 7% year over year and GAAP net income of $51.7 million, compared with $5.7 million a year earlier. The company also gave fiscal 2026 outlook, expecting revenue of $1.302 billion to $1.312 billion and GAAP net income of $2.24 to $2.33 per diluted share.
Q3 revenue was $322.2 million, up from $300.4 million a year earlier.
GAAP net income per diluted share was $0.59, versus $0.06 a year earlier; non-GAAP net income per diluted share rose 29% to $1.01.
Adjusted EBITDA was $141.8 million, up 20% year over year.
For the fiscal year ending January 31, 2026, the company expects non-GAAP net income per diluted share of $3.87 to $3.95.
HealthEquity reported results for the quarter ended July 31, 2025, with revenue of $325.8 million, up 9% from a year earlier, and GAAP net income of $59.9 million, or $0.68 per diluted share, up from $0.40. The company also set fiscal 2026 outlook calling for revenue of $1.290 billion to $1.310 billion and GAAP net income per diluted share of $2.11 to $2.28.
Q2 revenue was $325.8 million, up 9% from $299.9 million; adjusted EBITDA was $151.1 million, up 18%.
GAAP net income was $59.9 million, or $0.68 per diluted share, versus $35.8 million, or $0.40, a year earlier.
For the fiscal year ending January 31, 2026, the company expects revenue of $1.290 billion to $1.310 billion and adjusted EBITDA of $540 million to $560 million.
The company repurchased 0.7 million shares for $66.0 million in the quarter, with $351.8 million remaining authorized as of July 31, 2025.
HealthEquity reported first-quarter results for the period ended April 30, 2025, with revenue of $330.8 million, up 15%, and GAAP net income of $53.9 million, or $0.61 per diluted share, up from $0.33 a year earlier. The company said it increased its full-year fiscal 2026 guidance, now calling for revenue of $1.285 billion to $1.305 billion and GAAP net income per diluted share of $1.96 to $2.13.
Revenue of $330.8 million, up 15% from $287.6 million a year earlier; Adjusted EBITDA of $140.2 million, up 19%
GAAP net income of $53.9 million, or $0.61 per diluted share, versus $28.8 million, or $0.33, in the prior-year quarter
Fiscal 2026 outlook: revenue $1.285 billion to $1.305 billion; Adjusted EBITDA $530 million to $550 million; non-GAAP net income per diluted share $3.61 to $3.78
Company repurchased 0.7 million shares for $60.3 million in the quarter; $117.5 million remained authorized as of April 30, 2025
HealthEquity director Paul Black resigned from the board effective April 22, 2025, and the board reduced its size to ten members. The company said the resignation was not related to any disagreement over its operations, policies, or practices. The board will shrink further to nine members on April 30, 2025, when Jon Kessler's previously announced retirement takes effect.
Paul Black resigned from the Board of Directors on April 22, 2025, with no disagreement with the company cited
Board size reduced to ten members following Black's resignation
Board size will fall to nine members on April 30, 2025, after Jon Kessler retires
HealthEquity reported fiscal 2025 results for the year ended January 31, 2025, with revenue of $1.20 billion (up 20%) and GAAP net income of $96.7 million, or $1.09 per diluted share, up from $55.7 million, or $0.64, a year earlier. Fourth-quarter net income was flat at $26.4 million, while the company guided to fiscal 2026 revenue of $1.280 billion to $1.305 billion and GAAP net income per diluted share of $1.85 to $2.01.
Fiscal 2025 revenue of $1.20 billion, up 20% from $999.6 million; Adjusted EBITDA of $471.8 million, up 28%.
Fourth-quarter revenue of $311.8 million, up 19%; net income of $26.4 million, unchanged from the prior-year quarter.
Fiscal 2026 outlook: revenue of $1.280 billion to $1.305 billion; GAAP net income per diluted share of $1.85 to $2.01; Adjusted EBITDA of $525 million to $545 million.
Completed the BenefitWallet HSA portfolio acquisition for a purchase price of $425.0 million and repurchased 1.4 million shares for $122.2 million during the year.
HealthEquity reported year-end operating metrics for the fiscal year ended January 31, 2025, showing growth in HSAs, total accounts and HSA Assets. The company affirmed its fiscal 2025 and 2026 guidance and set March 18, 2025 as the date for its fourth quarter and fiscal 2025 results, which will give shareholders the first full financial results for the period. The filing does not include reported revenue, profit or earnings per share for the period.
HSAs rose 14% to 9.9 million as of January 31, 2025, from 8.7 million a year earlier
HSA Assets grew 27% to $32.1 billion, from $25.2 billion a year earlier
Total Accounts rose 9% to 17.0 million; new HSAs from sales in the quarter fell 5% to 471
The company affirmed its fiscal 2025 and 2026 outlook and will report fourth quarter and fiscal 2025 results on March 18, 2025
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every HealthEquity filing is on SEC EDGAR ↗. 8-K briefs of other companies →